Systemic lupus erythematosus flare following SARS-CoV2 infection: the implication of IFNα and anti-IFNα autoantibodies.
Mageau A, Nicaise Roland P, Goulenok T, Farkh C, Charles N, Sacre K. Clin Exp Rheumatol. 2022 Feb 16.

The involvement of type 1 interferon (IFN) and anti-type 1 IFN antibodies (Ab) in the pathophysiology of Systemic Lupus Erythematosus (SLE) and in the immune response during COVID-19 raises the concern of lupus flares induced by the SARS-CoV-2 infection. We report here the case of a patient in whom we were able to monitor the level of IFNα, anti-IFNα Ab and anti-DNA Ab before, during and after infection with COVID-19. The clinical evolution compared with the evolution of these immunological markers suggests a direct link between the viral infection, the drop in the level of anti-IFNα Ab and the lupus flare which followed.  

 
 
Tiphaine Goulenok, Chrystelle Francois, Céline Mendes, Fatima Farhi, Jean-Francois Alexandra, Diane Rouzaud, Thomas Papo, Karim Sacre. J Rheumatol. 2021 Oct 15;jrheum.210534. doi: 10.3899/jrheum.210534.
 
Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors.

Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, Vidal-Petiot E, Flamant M, Jondeau G, Cohen-Solal A, d’Ortho MP, Frija-Masson J. Eur Respir J. 2021 Aug 26;58(2):2101578. doi: 10.1183/13993003.01578-2021. PMID: 34385265
 
 
Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study.

Frija-Masson J, Debray MP, Boussouar S, Khalil A, Bancal C, Motiejunaite J, Galarza-Jimenez MA, Benzaquen H, Penaud D, Laveneziana P, Malrin R, Redheuil A, Donciu V, Lucidarme O, Taillé C, Guerder A, Arnoult F, Vidal-Petiot E, Flamant M, Similowski T, Morelot-Panzini C, Faure M, Lescure FX, Straus C, d’Ortho MP, Gonzalez-Bermejo J. Respir Med. 2021 Aug;184:106435. doi: 10.1016/j.rmed.2021.106435. PMID: 34020126
 
 
Time of bariatric surgery and hospitalization for SARS-Cov2: a Nationwide study
Poghosyan T , Rives-Lange C, Carette C, Girardeau Y ,Jannot AS , Czernichow S. Obes Surg. 2021 Aug;31(8):3893-3895. doi: 10.1007/s11695-021-05449-z

 

Renin-angiotensin system blockers and COVID-19.
Vidal-Petiot E, Gault N.  BMC Med. 2021;19(1):136. Published 2021 Jun 4. doi:10.1186/s12916-021-02012-6

 

SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study.
Mageau A, Aldebert G, Van Gysel D, Papo T, Timsit JF, Sacre K. Ann Rheum Dis. 2021 Mar 16:annrheumdis-2021-220010. doi: 10.1136/annrheumdis-2021-220010.

 

The Good Treatment, the Bad Virus, and the Ugly Inflammation: Pathophysiology of Kidney Involvement During COVID-19.
Le Stang MB, Desenclos J, Flamant M, Chousterman BG, Tabibzadeh N. Front Physiol. 2021 Mar 11;12:613019. doi: 10.3389/fphys.2021.613019. eCollection 2021. PMID: 33776785

 

Chronic use of Renin-Angiotensin-Aldosterone-System blockers and mortality in COVID-19: a multicenter prospective cohort and literature review.
Gault N, Esposito-Farese M, Revest M, Inamo J, Cabie A, Polard É, Hulot JS, Ghosn J, Chirouze C, Deconinck L, Diehl JL, Poissy J, Epaulard O, Lefèvre B, Piroth L, de Montmollin E, Oziol E, Etienne M, Laouenan C, Rossignol P, Costagliola D, Vidal-Petiot E; French-Covid cohort investigators and study group. Fundam Clin Pharmacol. 2021 Apr 20. doi: 10.1111/fcp.12683. Online ahead of print. PMID: 33876439

 

Arterial Thrombotic Events in Adult Inpatients With COVID-19.
Fournier M, Faille D, Dossier A, Mageau A, Nicaise Roland P, Ajzenberg N, Borie R, Bouadma L, Bunel V, Castier Y, Choquet C, Crestani B, Daugas E, Deconinck L, Descamps D, Descamps V, Dieudé P, Ducrocq G, Faucher N, Goulenok T, Guidoux C, Khalil A, Lavallée P, Lescure FX, Lortat-Jacob B, Mal H, Mutuon P, Pellenc Q, Steg PG, Taille C, Timsit JF, Yazdanpanah Y, Papo T, Sacré K. Mayo Clin Proc. 2021 Feb;96(2):295-303. doi: 10.1016/j.mayocp.2020.11.018. Epub 2020 Nov 27. PMID: 33549252

 

Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.
Flament H, Rouland M, Beaudoin L, Toubal A, Bertrand L, Lebourgeois S, Rousseau C, Soulard P, Gouda Z, Cagninacci L, Monteiro AC, Hurtado-Nedelec M, Luce S, Bailly K, Andrieu M, Saintpierre B, Letourneur F, Jouan Y, Si-Tahar M, Baranek T, Paget C, Boitard C, Vallet-Pichard A, Gautier JF, Ajzenberg N, Terrier B, Pène F, Ghosn J, Lescure X, Yazdanpanah Y, Visseaux B, Descamps D, Timsit JF, Monteiro RC, Lehuen A. Nat Immunol. 2021 Feb 2. doi: 10.1038/s41590-021-00870-z. Online ahead of print. PMID: 33531712

 

Impact of the first Covid-19 outbreak on liver transplantation activity in France: A snapshot.
Turco C, Lim C, Soubrane O, Malaquin G, Kerbaul F, Bastien O, Conti F, Scatton O. Clin Res Hepatol Gastroenterol. 2020 Nov 8:101560. doi: 10.1016/j.clinre.2020.10.005. Online ahead of print. PMID: 33176991

 

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area.
Amaddeo G, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, Blaise L, Ganne-Carrié N, Séror O, Larrey E, Lim C, Scatton O, El Mouhadi S, Ozenne V, Paye F, Balladur P, Dohan A, Massault PP, Pol S, Burgio MD, Vilgrain V, Sepulveda A, Cauchy F, Luciani A, Sommacale D, Leroy V, Roudot-Thoraval F, Bouattour M, Nault JC; Paris Liver Cancer Group. JHEP Rep. 2021 Feb;3(1):100199. doi: 10.1016/j.jhepr.2020.100199. Epub 2020 Dec 22. PMID: 33163949

 

Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment.
Lahens A, Mullaert J, Gressens S, Gault N, Flamant M, Deconinck L, Joly V, Yazdanpanah Y, Lescure FX, Vidal-Petiot E. J Hypertens. 2021 Feb 1;39(2):367-375. doi: 10.1097/HJH.0000000000002658. PMID: 33021511

 

Lipoprotein concentrations over time in the intensive care unit COVID-19 patients: Results from the ApoCOVID study.
Tanaka S, De Tymowski C, Assadi M, Zappella N, Jean-Baptiste S, Robert T, Peoc’h K, Lortat-Jacob B, Fontaine L, Bouzid D, Tran-Dinh A, Tashk P, Meilhac O, Montravers P. PLoS One. 2020 Sep 24;15(9):e0239573. doi: 10.1371/journal.pone.0239573. eCollection 2020. PMID: 32970772

 

Efficacy of Chest CT for COVID-19 Pneumonia Diagnosis in France.
Herpe G, Lederlin M, Naudin M, Ohana M, Chaumoitre K, Gregory J, Vilgrain V, Freitag CA, De Margerie-Mellon C, Flory V, Ludwig M, Mondot L, Fitton I, Jacquier ARR, Ardilouze P, Petit I, Gervaise A, Bayle O, Crombe A, Mekuko Sokeng M, Thomas C, Henry G, Bliah V, Le Tat T, Guillot MS, Gendrin P, Garetier M, Bertolle E, Montagne C, Langlet B, Kalaaji A, Kayayan H, Desmots F, Dhaene B, Saulnier PJ, Guillevin R, Bartoli JM, Beregi JP, Tasu JP. Radiology. 2021 Feb;298(2):E81-E87. doi: 10.1148/radiol.2020202568. Epub 2020 Sep 1. PMID: 32870139

 

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic.
Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169. Epub 2020 Aug 4. PMID: 32835190

 

Extension of COVID-19 pulmonary parenchyma lesions based on real-life visual assessment on initial chest CT is an independent predictor of poor patient outcome.
Grégory J, Raynaud L, Galy A, Corre F, Bijot JC, Nguyen Y, Vilgrain V. Infect Dis (Lond). 2020 Nov;52(11):838-840. doi: 10.1080/23744235.2020.1792544. Epub 2020 Jul 13. PMID: 32657190

 

No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
Biquard L, Valla D, Rautou PE. J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30. PMID: 32360995